William E. lv Delaney net worth and biography

William Delaney Biography and Net Worth

Insider of Assembly Biosciences

William Delaney, PhD joined Assembly as Chief Scientific Officer, Virology in May 2020. Prior to joining Assembly, he most recently served as Executive Director, Biology at Gilead. During his 20-year career at the company, he headed the Viral Hepatitis & Herpes Discovery Biology Groups and served as the Research Therapeutic Area Head for HBV. He began his career as a Research Scientist, Clinical Virology at Gilead and later transitioned into Drug Discovery where he held positions of increasing responsibility. Over the course of his career, he has contributed to the development of several marketed products, including Hepsera®, Viread®, and Vemlidy® for HBV and Sovaldi®, Harvoni®, Epclusa®, and Vosevi® for HCV. He earned a BS in Biotechnology from the University of Delaware and a PhD in Cell and Molecular Biology from the Penn State College of Medicine. In addition, he was a Postdoctoral Fellow at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Department of Research & Molecular Development.

What is William E. lv Delaney's net worth?: The estimated net worth of William E. lv Delaney is at least $192.95 thousand as of May 31st, 2022. Dr. Delaney owns 6,368 shares of Assembly Biosciences stock worth more than $192,950 as of May 15th. This net worth approximation does not reflect any other assets that Dr. Delaney may own. Learn More about William E. lv Delaney's net worth.
How do I contact William E. lv Delaney?: The corporate mailing address for Dr. Delaney and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on William E. lv Delaney's contact information.
Has William E. lv Delaney been buying or selling shares of Assembly Biosciences?: William E. lv Delaney has not been actively trading shares of Assembly Biosciences during the last ninety days. Learn More on William E. lv Delaney's trading history.
Who are Assembly Biosciences' active insiders?: Assembly Biosciences' insider roster includes Jeanette Bjorkquist (Insider), William Delaney (Insider), Michael Houghton (Director), John McHutchison (CEO), Jason Okazaki (CEO), Timothy Springer (Director), and Nicole White (Insider). Learn More on Assembly Biosciences' active insiders.

William E. lv Delaney Insider Trading History at Assembly Biosciences

William E. lv Delaney Buying and Selling Activity at Assembly Biosciences

Assembly Biosciences Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Today's Range

Now: $29.17

$28.89

$29.99

50 Day Range

MA: $28.78

$26.33

$31.72

2 Week Range

Now: $29.17

$12.76

$39.71

Volume

48,778 shs

Average Volume

104,877 shs

Market Capitalization

$463.51 million

P/E Ratio

N/A

Dividend Yield